Can a common eye supplement fight cancer? new trial begins
NCT ID NCT05232409
First seen Jun 05, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This early-stage trial is testing whether a dietary supplement called zeaxanthin, taken alone or with the immunotherapy drug pembrolizumab, is safe for people with advanced solid tumors that have not responded to standard treatments. The study will enroll 72 participants to find the highest safe dose and check for side effects. It does not aim to cure cancer at this point, but to lay the groundwork for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Valley Hospital-Luckow Pavilion
RECRUITINGParamus, New Jersey, 07652, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zeaxanthin (a dietary supplement) alone or combined with pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial focused on safety and dosing, not effectiveness. The supplement may not shrink tumors or may cause side effects. Success is uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.